Cancer Family
Mast Cell Neoplasm
CI-CAN-00000257Explore in graph →
HematologicNon-malignant9 active trials2 approved drugs4 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000257Explore in graph →
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04910685 | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | recruiting | Phase 2 / Phase 3 | 534 | Blueprint Medicines CorporationINDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT03401060 | Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis(DenosuMast) | completed | Phase 3 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 31, 2026 |
| clinicaltrials |
| NCT04333108 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | unknown | Phase 3 | 140 | AB ScienceINDUSTRY | 8 | May 6, 2023 | clinicaltrials |
| NCT05084872 | Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients(HCQMa) | unknown | Phase 2 / Phase 3 | 30 | University Hospital, ToulouseOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00814073 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis(AB06006) | completed | Phase 3 | 135 | AB ScienceINDUSTRY | 2 | Dec 3, 2019 | clinicaltrials |
| NCT01481909 | Study on Mastocytosis for Rupatadine Treatment(SMART) | completed | Phase 2 / Phase 3 | 30 | Marcus MaurerOTHER | 1 | Nov 3, 2016 | clinicaltrials |
| NCT01602939 | Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis | unknown | Phase 2 / Phase 3 | 10 | Hospital Virgen de la SaludOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01333293 | The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients(XOLMA) | completed | Phase 2 / Phase 3 | 17 | University of ZurichOTHER | 1 | Jan 18, 2016 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials